Article
The emerging significance of secondary germline testing in cancer genomics.
The Journal of pathology - 1 Apr 2018
Mandelker Diana, Zhang Liying
Abstract excerpt
Many clinical laboratories now sequence the tumors from advanced cancer patients to identify oncogenic drivers and guide targeted therapies and clinical trials. One limitation of tumor sequencing is that it cannot distinguish between tumor-specific somatic (acquired) mutations and patients' germline (constitutional) variants. To definitively identify somatic variants, some clinical labs sequence both a normal...
Topics
Join the communities discussing this publication.